400 related articles for article (PubMed ID: 27486141)
1. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
Kuppens RJ; Donze SH; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
[TBL] [Abstract][Full Text] [Related]
2. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
Damen L; Grootjen LN; Juriaans AF; Donze SH; Huisman TM; Visser JA; Delhanty PJD; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2021 May; 94(5):774-785. PubMed ID: 33296519
[TBL] [Abstract][Full Text] [Related]
3. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.
Einfeld SL; Smith E; McGregor IS; Steinbeck K; Taffe J; Rice LJ; Horstead SK; Rogers N; Hodge MA; Guastella AJ
Am J Med Genet A; 2014 Sep; 164A(9):2232-9. PubMed ID: 24980612
[TBL] [Abstract][Full Text] [Related]
4. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.
Miller JL; Tamura R; Butler MG; Kimonis V; Sulsona C; Gold JA; Driscoll DJ
Am J Med Genet A; 2017 May; 173(5):1243-1250. PubMed ID: 28371242
[TBL] [Abstract][Full Text] [Related]
5. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.
Hollander E; Levine KG; Ferretti CJ; Freeman K; Doernberg E; Desilva N; Taylor BP
J Psychiatr Res; 2021 May; 137():643-651. PubMed ID: 33190843
[TBL] [Abstract][Full Text] [Related]
6. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
7. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients.
Tauber M; Mantoulan C; Copet P; Jauregui J; Demeer G; Diene G; Rogé B; Laurier V; Ehlinger V; Arnaud C; Molinas C; Thuilleaux D
Orphanet J Rare Dis; 2011 Jun; 6():47. PubMed ID: 21702900
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of intranasal oxytocin in patients with Prader-Willi syndrome: A systematic review and meta-analysis.
Shalma NM; Alsharabasy MA; Taha AM; Alsawareah A; Manirambona E; Ahmed SK; Mohamed MR; Taha NA; Abd-ElGawad M
Diabetes Metab Syndr; 2023 Feb; 17(2):102711. PubMed ID: 36774885
[TBL] [Abstract][Full Text] [Related]
10. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
Dykens EM; Miller J; Angulo M; Roof E; Reidy M; Hatoum HT; Willey R; Bolton G; Korner P
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925684
[TBL] [Abstract][Full Text] [Related]
11. The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome.
Tauber M; Boulanouar K; Diene G; Çabal-Berthoumieu S; Ehlinger V; Fichaux-Bourin P; Molinas C; Faye S; Valette M; Pourrinet J; Cessans C; Viaux-Sauvelon S; Bascoul C; Guedeney A; Delhanty P; Geenen V; Martens H; Muscatelli F; Cohen D; Consoli A; Payoux P; Arnaud C; Salles JP
Pediatrics; 2017 Feb; 139(2):. PubMed ID: 28100688
[TBL] [Abstract][Full Text] [Related]
12. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
[TBL] [Abstract][Full Text] [Related]
13. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings.
Johnson L; Manzardo AM; Miller JL; Driscoll DJ; Butler MG
Am J Med Genet A; 2016 Mar; 170(3):594-601. PubMed ID: 26615966
[TBL] [Abstract][Full Text] [Related]
15. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
Kuppens RJ; Bakker NE; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Donze SH; Festen DA; van Alfen-van der Velden JA; Stijnen T; Hokken-Koelega AC
J Clin Endocrinol Metab; 2016 Nov; 101(11):4110-4116. PubMed ID: 27552545
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
[TBL] [Abstract][Full Text] [Related]
17. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.
De Waele K; Ishkanian SL; Bogarin R; Miranda CA; Ghatei MA; Bloom SR; Pacaud D; Chanoine JP
Eur J Endocrinol; 2008 Oct; 159(4):381-8. PubMed ID: 18603572
[TBL] [Abstract][Full Text] [Related]
18. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.
Kuppens RJ; Bakker NE; Siemensma EP; Donze SH; Stijnen T; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2017 Feb; 86(2):297-304. PubMed ID: 27689944
[TBL] [Abstract][Full Text] [Related]
19. Dyssynchrony and perinatal psychopathology impact of child disease on parents-child interactions, the paradigm of Prader Willi syndrom.
Viaux-Savelon S; Rosenblum O; Guedeney A; Diene G; Çabal-Berthoumieu S; Fichaux-Bourin P; Molinas C; Faye S; Valette M; Bascoul C; Cohen D; Tauber M
J Physiol Paris; 2016 Nov; 110(4 Pt B):427-433. PubMed ID: 28823614
[TBL] [Abstract][Full Text] [Related]
20. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.
Goldstone AP; Holland AJ; Butler JV; Whittington JE
Int J Obes (Lond); 2012 Dec; 36(12):1564-70. PubMed ID: 22270375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
